- AGC Biologics partners with CompleCure to develop the manufacturing process for a novel anti-cancer therapeutic using AMDC technology.
- The development will take place at AGC’s Chiba facility, focused on the complex protein component of the treatment.
AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO), announced a strategic service agreement with CompleCure to support the development of a novel anti-cancer therapeutic. The therapy, based on Antibody Mimetics Drug Conjugate (AMDC) technology, represents a new approach to cancer treatment, specifically targeting breast cancer.
The manufacturing process for the therapeutic’s protein component will be developed at AGC Biologics’ Chiba, Japan facility. This complex protein has a tetrameric structure and requires advanced microbial expression technology, an area in which AGC Biologics has significant expertise. The agreement allows AGC to utilize its established capabilities in process development and production for this innovative treatment.
CompleCure chose AGC Biologics based on its 30-year track record as a CDMO and its ability to propose rapid, innovative solutions. The collaboration will continue at the Chiba site through to production, ensuring a smooth transition for further manufacturing steps.
Commenting on the partnership, CompleCure stated, “AGC Biologics’ expertise in flexible and advanced manufacturing solutions made them the ideal partner for our project.” This agreement marks a step forward in the commercialization of AMDC-based therapies, which aim to improve the quality of life for cancer patients.
Stay ahead of trends and best practices
